Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies
Kap‐Sun Yeung(Bristol-Myers Squibb (United States)), John F. Kadow(Bristol-Myers Squibb (United States)), Julie A. Lemm(Bristol-Myers Squibb (United States)), Katherine A. Grant-Young(Bristol-Myers Squibb (United States)), Changhong Wan(Bristol-Myers Squibb (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States)), Andrew Nickel(Bristol-Myers Squibb (United States)), Roy Haskell(Bristol-Myers Squibb (United States)), Ying-Kai Wang(Bristol-Myers Squibb (United States)), Prashantha Gunaga(Bristol-Myers Squibb (India)), Mengping Liu(China University of Geosciences (Beijing)), Karen Rigat(Bristol-Myers Squibb (United States)), Mark R. Witmer(Bristol-Myers Squibb (United States)), Alicia Ng(Bristol-Myers Squibb (United States)), Joseph Raybon(Bristol-Myers Squibb (United States)), Umesh Hanumegowda(Bristol-Myers Squibb (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Kyle Parcella(Bristol-Myers Squibb (United States)), Qi Gao(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Bender(Bristol-Myers Squibb (United States)), S. Sheriff(Bristol-Myers Squibb (United States)), Dawn D. Parker, Brett R. Beno(Franklin University), Prakash Anjanappa(Bristol-Myers Squibb (India)), Matthew G. Soars(Bristol-Myers Squibb (United States)), Susan B. Roberts(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Kevin Kish(Bristol-Myers Squibb (United States)), Min Gao(Central South University), K. Selvakumar(Bristol-Myers Squibb (India)), Dennis M. Grasela(Bristol-Myers Squibb (United States)), Yue‐Zhong Shu(Bristol-Myers Squibb (United States)), Kenneth S. Santone(Bristol-Myers Squibb (Germany)), Xiaoliang Zhuo(Bristol-Myers Squibb (United States)), Kathy Mosure(Bristol-Myers Squibb (United States)), Rajesh O. Bora(Bristol-Myers Squibb (India)), Elizabeth Colston(Bristol-Myers Squibb (United States))
Cited by 31
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
|Nature Immunology|2021|422
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
|Chemical Research in Toxicology|1998|312
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
|Nature Biotechnology|2024|258